Valuation dashboard for Genelux Corporation (GNLX) with P/E N/A, P/B 5.99, EV/EBITDA -3.00 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer.
Analysis Summary
Trailing-twelve-month margins: gross margin -17.6%, operating margin -4452.0%, net margin -4224.1%.
At the current price of $2.34, GNLX has negative trailing earnings (P/E not meaningful) and an ROE of -195.42%. Market capitalisation stands at $105M.
Balance sheet quality for GNLX: current ratio of 2.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 5.99 |
| EV / EBITDA | -3.00 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-0.01 |
| vs Current Price | -100.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GNLX | Genelux Corporation | $105M | 5.99 | -195.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.34 |
| Market Cap | $105M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -195.42% |
| Return on Invested Capital | -192.18% |
| Return on Assets | -128.96% |
| Gross Margin | -1762.50% |
| Operating Margin | -445200.00% |
| Net Margin | -422412.50% |
Related companies: ACIU · ALDX · CADL · CLLS · CTNM · DRTS · LXEO
Explore sector: Healthcare · Biotechnology
More sections of GNLX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks